ArticleThe journal of sexual medicine2026
Prevalence and predictors of bone density loss in men with low testosterone.
Article in The journal of sexual medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
backgroundLow testosterone (T) is associated with several sequelae, including a high prevalence of bone density loss (BDL).
aimWe aimed to identify predictors of BDL in men with low T.
methodsThe sample included (1) men ≥50 years old, (2) with low total T levels (<300 ng/dL using LCMS on 2 early morning blood draws), (3) who had dual-energy X-ray absorptiometry (DEXA) within 6 months of T measurement. Men with prior T therapy were excluded. On DEXA, osteopenia was defined as a T score between -1.0 and -2.5, and osteoporosis as a T score below -2.5. Additionally, demographics and comorbidity data were collected. We report BDL rates and identify predictors of any BDL using logistic regression. OUTCOMES: Bone density loss, which was defined as the presence of osteopenia or osteoporosis.
resultsNine hundred ninety-seven men were analyzed, with a median age of 64 (IQR 59, 70) years. Median total T was 202 (IQR: 107, 256) ng/dL, median free T 5.8 (IQR: 4.3, 7.5) ng/dL. 24% had a total T ≤ 100 ng/dL. Thirty-three percent had ≥3 comorbidities. Seventy-four percent of our cohort had an oncological history; most of them had a history of prostate cancer. Bone density loss was present in 36% of the patients (89% osteopenia, 11% osteoporosis). On multivariable analysis, significant predictors of BDL were lower total T levels (OR = 1.09), older age (OR = 1.59), and the presence of ≥3 comorbidities (OR = 1.60). CLINICAL IMPLICATIONS: It is critical to be aware of the significant prevalence of BDL in men with low T. Early identification may enable targeted counseling, the initiation of preventive or therapeutic strategies to improve bone density outcomes, and the reduction of the risk of fractures and other serious skeletal complications. STRENGTHS & LIMITATIONS: Limitations related to retrospective design, including selection bias and unmeasured confounding factors. Another limitation is that most cases had an oncological history. However, several strengths include the use of a large, systematically audited database; T labs were assessed using gold-standard methodology; and bone mineral density was assessed using a standardized scanning protocol.
conclusionIn our cohort of older men, most with oncological history and low T, around one-third had BDL, and around 10% of those with BDL had osteoporosis. Lower T levels, older age, and a greater number of comorbidities were significant predictors of BDL.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.